导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.70% | 1469/4773 |
| 近一周 | -1.19% | 2251/5467 |
| 近一月 | -11.76% | 5110/5421 |
| 近一季 | -20.65% | 4858/5238 |
| 近半年 | 1.33% | 1317/4931 |
| 近一年 | 5.60% | 1498/4400 |
| 近两年 | 118.11% | 435/2954 |
| 近三年 | 68.79% | 355/2253 |
| 成立以来 | 120.11% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.61% 1884/4961 |
37.09% 856/5312 |
- - |
- - |
| 2025 | 50.96% 455/4813 |
-1.71% 2754/3635 |
3.24% 1089/4076 |
50.32% 314/4524 |
-1.04% 2793/4813 |
| 2024 | 14.25% 1063/3463 |
-4.00% 1594/2808 |
-6.48% 1963/3014 |
29.33% 164/3129 |
-1.60% 1767/3463 |
| 2023 | -19.07% 1841/2656 |
2.13% 1441/2280 |
-7.14% 1788/2385 |
-9.55% 1849/2515 |
-5.65% 1443/2655 |
| 2022 | -28.75% 1579/2207 |
-19.81% 1494/1919 |
5.76% 832/2016 |
-18.10% 1682/2113 |
2.57% 897/2208 |
| 2021 | 10.70% 421/1822 |
-7.33% 1061/1255 |
25.50% 87/1330 |
-6.83% 993/1466 |
2.16% 673/1822 |
| 2020 | 63.32% 106/1250 |
3.98% 96/1028 |
30.34% 59/1067 |
4.99% 937/1164 |
14.79% 247/1184 |
| 2019 | - - |
- - |
- - |
7.07% 104/850 |
9.83% 186/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 富国创业板ETF VS. 长安沪深300非周期A(740101) |